INVESTOR PRESENTATION Q4 2022 FEBRUARY 8, 2023 Nasdaq: ATRA Forward-L ...

INVESTOR PRESENTATION Q4 2022 FEBRUARY 8, 2023 Nasdaq: ATRA Forward-L ...

Financial Performance - For the year ended December 31, 2022, the company reported a net loss of $228.3 million[183]. - The company has not generated any revenue from commercial product sales to date and relies on commercialization agreements for potential future revenue[189]. - As of December 31, 2022, the company had total cash, cash equivalents, and short-term investments of $242.8 million, expected to fund operations into the second quarter of 2024[193]. - The company anticipates substantial additional financing will be required to continue product development and operations, with no committed external funding sources[191][194]. - The company expects to continue incurring significant operating losses as it invests in research and development for its product candidates[184]. - The company received $31.0 million in cash from HealthCare Royalty Partners under the HCRx Agreement for future royalty payments related to Ebvallo in the EU[345]. - Future capital needs may require the company to issue substantial amounts of common stock, potentially resulting in dilution for existing shareholders[365]. - The company does not anticipate paying cash dividends in the foreseeable future, with capital appreciation being the sole source of potential gain for shareholders[364]. Product Development and Regulatory Approval - The company has outlicensed commercialization rights for its product Ebvallo in the EU to Pierre Fabre, with milestone payments dependent on regulatory approvals and market success[189]. - The company has a limited operating history, making it difficult to assess future viability and success in commercialization efforts[185]. - The company is early in its development efforts, with most product candidates still in preclinical development, which poses significant risks to future revenue generation[200]. - The success of the company's product candidates will depend on positive clinical study results and obtaining necessary regulatory approvals[201]. - The company has only one product, Ebvallo, that has gained regulatory approval in the EU, while prioritized clinical-stage product candidates include ATA188 and tab-cel in the U.S.[209]. - The approval process for product candidates is unpredictable and typically takes many years, influenced by various factors including regulatory authority discretion and the novel nature of the products[211]. - The FDA has limited experience with regulating T-cell immunotherapies, which may complicate the approval process for the company's product candidates[211]. - The company may face significant delays in obtaining regulatory approval due to the ongoing COVID-19 pandemic, which has impacted clinical trials and manufacturing capabilities[204][215]. - The company has experienced delays in clinical site initiation and patient enrollment due to the COVID-19 pandemic, affecting the progress of clinical trials[206]. - The company may need to conduct additional clinical trials to support a BLA submission for tab-cel, which could result in considerable delays[214]. - The company is subject to ongoing post-marketing obligations for Ebvallo, and failure to meet these obligations could lead to changes or suspension of its marketing authorization[211]. - Regulatory authorities may require more information or additional data to support approval, potentially delaying commercialization plans[214]. - The regulatory approval process for novel T-cell product candidates and next-generation CAR T programs is complex and costly, potentially leading to delays and limited indications upon approval[217]. - The company is facing challenges in obtaining regulatory approval from the FDA and other authorities due to limited experience with allogeneic T-cell products[218]. - The ongoing clinical trials may be adversely affected by safety issues or clinical holds, impacting the development of related product candidates[217]. - The company must establish reliable processes for procuring and processing T cells from donors, which is critical for the success of its product candidates[218]. - Manufacturing processes must yield stable, safe, and potent products, which is essential for scalability and profitability[221]. - The company plans to use independent assessments for regulatory approvals, which may differ from investigator-reported assessments[227]. - Clinical studies may face delays due to various factors, including regulatory agreements and patient enrollment challenges[231]. - Patient enrollment is significantly influenced by the nature of the patient population and competition from other clinical studies[234]. - The company acknowledges that interim data from clinical studies may change as more patient data become available, impacting regulatory approval prospects[229]. - Enrollment in Phase 3 studies of tab-cel for patients with EBV+ PTLD was slower than anticipated, impacting development timelines[236]. - The company activated additional clinical sites for the ALLELE study in 2018, leading to increased enrollment later in the year[236]. - Delays in clinical trial site initiation and patient enrollment were experienced due to the ongoing COVID-19 pandemic[237]. - The company relies on CROs and other third parties for clinical studies, which may introduce risks and reduce control over these activities[237]. - Regulatory compliance with Good Clinical Practice (GCP) is essential, and failure to comply may result in unreliable clinical data and delayed approvals[237]. - The FDA has granted breakthrough therapy designation (BTD) for tab-cel, but this does not guarantee faster development or approval[249]. - The company expects to seek initial approval of tab-cel in patients with relapsed or refractory metastatic disease, with potential for later lines of treatment[243]. - Orphan drug designation has been granted for tab-cel, providing a period of marketing exclusivity if approved[246]. - The potential target population for tab-cel is limited, as it primarily addresses patients who have failed prior treatments[245]. - Fast track designation for ATA188 was received, but it does not assure a faster development process or ultimate marketing licensure[253]. - The company faces significant regulatory challenges in obtaining approvals for its product candidates in international markets, which may hinder commercialization efforts[255]. - Even with regulatory approval, ongoing compliance with FDA and foreign authorities is required, which includes monitoring for safety and potential labeling changes[256]. - Manufacturing processes are complex and subject to regulatory scrutiny, with risks of contamination and equipment failure that could impact production yields[267]. - The company must scale up production significantly to meet market demand for approved product candidates, which poses additional challenges[273]. - Delays in receiving regulatory approvals for manufacturing at contract manufacturing organizations (CMOs) could limit development activities and revenue generation[270]. Intellectual Property and Competition - The company relies on a combination of patents and trade secrets for intellectual property protection, which is critical for its competitive advantage[292]. - The patentability and enforceability of biotechnology patents are uncertain, which could affect the company's ability to protect its innovations[293]. - The company has filed numerous patent applications covering its products and candidates, but there is no assurance that any patents will be issued or that they will be enforceable[298]. - The lifespan of patents is generally 20 years from the filing date, and delays in clinical studies or regulatory approvals could reduce the exclusivity period for marketing products[300]. - The company may face significant costs and time-consuming litigation if sued for infringing third-party intellectual property rights, which could hinder development and commercialization efforts[302]. - The company holds rights under license agreements with partners, and any breach could adversely affect its ability to develop and commercialize products[310]. - Intellectual property rights may not be adequately protected in foreign jurisdictions, leading to potential competition from infringing products[308]. - The company may need to engage in legal proceedings to enforce its intellectual property rights, which could be expensive and time-consuming[312]. - There is a risk that confidential information could be compromised during intellectual property litigation due to extensive discovery requirements[315]. - The company may be required to obtain licenses from third parties to continue using certain technologies, but there is no guarantee that these licenses can be obtained on commercially reasonable terms[297]. - The government has certain rights to patent rights and technology developed with its funding, which could impact the company's ability to commercialize related products[301]. - The company may face challenges in protecting its intellectual property rights globally, particularly in jurisdictions with less favorable legal systems for enforcement[309]. - The company faces significant competition in the pharmaceutical and biotechnology sectors, with numerous competitors developing products that may be safer, more effective, or less expensive[336]. - There are currently no FDA-approved products for the treatment of EBV+ PTLD, with Ebvallo being the only EC-approved product for this indication[337]. - The MS market has at least 20 therapies approved in the U.S. and EU, including generics, leading to high competition[338]. - The approval of biosimilars could significantly impact the company's business by introducing lower-cost alternatives to its products[348]. Market and Reimbursement Challenges - Coverage and adequate reimbursement from third-party payors are critical for the successful commercialization of products, with potential delays in obtaining such coverage[322]. - Legislative changes, including the Affordable Care Act, have significantly impacted the U.S. pharmaceutical industry and may affect pricing and reimbursement for products[325]. - The company may experience challenges in obtaining regulatory approval and navigating pricing regulations due to ongoing healthcare reform initiatives[325]. - There is a trend of increasing cost containment efforts by government authorities and payors, which may adversely affect demand for the company's products[329]. - The company must provide clinical evidence to payors beyond regulatory approval data to secure coverage for its products[323]. - The Inflation Reduction Act allows Medicare to establish a "maximum fair price" for certain drugs starting in 2026, impacting pricing strategies[331]. - The company may face significant costs and delays in the reimbursement process, which could materially affect its financial condition[324]. Operational and Workforce Considerations - A workforce reduction of approximately 20% was announced in August 2022 to prioritize key research and development programs[197]. - As of December 31, 2022, the company had 334 employees after a workforce reduction of approximately 20% announced in August 2022[352]. - The company has experienced significant workforce reductions, which could impede the achievement of corporate objectives[373]. - The management must improve operational and managerial systems to support future growth and development activities[353]. - The company may face challenges in managing relationships with strategic partners and suppliers as operations expand[353]. - The company faces intense competition for skilled personnel, which may limit its ability to hire and retain qualified employees[374]. - Employee retention strategies include equity awards that vest over time, but their value is affected by stock price fluctuations[374]. Compliance and Regulatory Risks - Compliance with healthcare laws and regulations is critical, as violations could lead to significant civil, criminal, and administrative penalties[378]. - The company is exposed to risks related to employee misconduct, which could result in regulatory sanctions and harm its reputation[380]. - Future operations may be impacted by the need to comply with various federal and state healthcare laws, including the Anti-Kickback Statute and HIPAA[375]. - The company’s business arrangements with third parties must adhere to applicable healthcare laws, which may involve substantial costs[378]. - Noncompliance by healthcare providers or entities associated with the company could lead to significant sanctions, affecting business operations[378]. - The company’s marketing practices and relationships with healthcare providers are governed by strict regulations, which could constrain business operations[375]. - Potential exposure under healthcare laws will increase significantly if the company obtains FDA approval for its product candidates[375]. - The company must navigate complex state and foreign laws that may impose additional compliance requirements beyond federal regulations[377].

Financial Data and Key Metrics Changes - For Q3 2022, Atara Biotherapeutics ended with approximately $265 million in cash, which is expected to fund operations into Q1 2024 [20] - The company anticipates a reduction in future operating cash burn following a recent restructuring [20] Business Line Data and Key Metrics Changes - The tab-cel therapy, under the trade name Ebvallo, received a positive opinion from the CHMP for its first indication, with a launch planned in Europe for Q1 2023 [5][6] - The overall response rate for the Phase 3 ALLELE study in EBV-positive PTLD was reported at 51.2%, with a median overall survival of 18.4 months [13][62] Market Data and Key Metrics Changes - The company is preparing for the launch of Ebvallo in Europe, which is expected to have significant pricing potential in an ultra-rare disease market [6] - The U.S. market for tab-cel is projected to have peak sales potential over $500 million per year across multiple indications [8][71] Company Strategy and Development Direction - Atara is seeking a commercial partner in the U.S. to avoid further investment and to extend its cash runway while maximizing the value of tab-cel [8][57] - The company is focused on leveraging its clinical data and regulatory discussions to facilitate a BLA submission without the need for new clinical trials [67] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the transformative potential of tab-cel and ATA188, particularly in addressing significant unmet medical needs in their respective markets [5][15] - The company is optimistic about the upcoming data readout from the Phase 2 EMBOLD study for ATA188, expected in October 2023, which could serve as a significant value inflection point [71] Other Important Information - Atara has treated over 400 patients with tab-cel in clinical settings, which is expected to support the BLA submission process [68] - The company has received fast track designations from the FDA for both tab-cel and ATA188, indicating regulatory support for their development [10] Q&A Session Summary Question: Guidance on EU tab-cel revenues and logistical hurdles - Management is not planning to provide revenue guidance for Europe at this stage but will discuss pricing at the time of launch [24] - Logistical hurdles are minimal as the company has experience in delivering allogeneic cell therapies efficiently [25] Question: Number of patients treated with commercial formulation for tab-cel - Management did not disclose specific numbers but confirmed constructive dialogues with the FDA regarding the clinical data from patients treated with commercial material [31] Question: Data presentation at ESMO for ATA2271 - Safety and PK data will be presented, including details on the fatal SAE that led to the pause in enrollment [40] Question: Clinical data package requirements for tab-cel - The upcoming Type B meeting with the FDA will discuss clinical data package requirements, with a focus on leveraging existing clinical experience [66] Question: Strategic rationale for U.S. partnership - A partnership is seen as beneficial to avoid commercialization costs and to leverage existing commercial structures in the U.S. [57]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Utpal Koppikar - CFO Jakob Dupont - EVP and Global Head of Research and Development AJ Joshi - Chief Medical Officer Conference Call Participants Salim Syed - Mizuho Tessa Romero - JPMorgan John Newman - Canaccord Ernesto Rodriguez Dumont - Cowen & Co. Michael DiFiore - Evercore ISI Tommie Reerink - Goldman Sachs C ...

Tab-cel® Program - Atara submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tab-cel® in November 2021, with potential European Commission (EC) approval anticipated in Q4 2022[10, 34] - Phase 3 ALLELE study data presented at ASH 2021 demonstrated a 50% Objective Response Rate (ORR) across Hematopoietic Cell Transplant (HCT) and Solid Organ Transplant (SOT) cohorts[38] - In responders from the Phase 3 ALLELE study, the Overall Survival (OS) at 1 year was 100% for HCT and 82.5% for SOT[38] - Atara received an upfront payment of $45 million and is eligible to receive up to ~$320 million in milestones, plus tiered royalties from Pierre Fabre for commercializing Tab-cel® in Europe, Middle East, Africa, and other select emerging markets[52] ATA188 Program - Up to ~1.2 million Multiple Sclerosis (MS) patients worldwide have a progressive form of the disease (PMS)[23, 64] - A longitudinal analysis identified Epstein-Barr Virus (EBV) as the required trigger for multiple sclerosis, with the risk of MS increasing 32-fold after EBV infection[75] - Atara is planning for two Phase 3 randomized pivotal studies focused on non-active progressive MS, with the primary endpoint of confirmed EDSS (Expanded Disability Status Scale) improvement at 12 months[74, 107, 109] CAR T Portfolio - Atara received $60 million in cash upon signing and is eligible to receive up to $610 million in development, regulatory, and commercial milestone payments, plus tiered royalties up to low double-digit percentage of net sales from Bayer for the mesothelin CAR T program (ATA3271) and autologous program (ATA2271)[137] - In an Investigator Sponsored Trial (MSKCC), 83% (5/6) of R/R B-ALL, NHL and CLL patients had durable Complete Response (CR) with median follow up of 26.9 months after receiving partially HLA matched EBV CD19 CAR T cells manufactured from third-party donors[145] - ATA3271 IND Submission is expected in Q4 2022[22, 138, 142]

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2022 Results Conference Call May 5, 2022 4:30 PM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Utpal Koppikar - Chief Financial Officer Jakob Dupont - EVP and Global Head of Research and Development AJ Joshi - Chief Medical Officer Kristin Yarema - Chief Commercial Officer Conference Call Participants Salim Syed - Mizuho Tessa Romero - JPMorgan John Newman - Canaccord Marc Frahm - Cowen and Company Ben Burnett - ...